Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression
Wendy W. J. Unger(Erasmus MC), Yvette van Kooyk(Amsterdam University Medical Centers), Steef Engels(University Medical Center), Christian T. Mayer(National Institutes of Health), Luciana Berod(Johannes Gutenberg University Mainz), Manja Litjens(Utrecht University), Franz Puttur(Asthma UK), Hakan Kalay(Amsterdam UMC Location Vrije Universiteit Amsterdam), Ingeborg Streng‐Ouwehand(Amsterdam UMC Location Vrije Universiteit Amsterdam), Tim Sparwasser(Johannes Gutenberg University Mainz), Maurizio Perdicchio(Roche (Switzerland)), Christina Hesse(Helmholtz Centre for Infection Research)
Cited by 36
Related Papers
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
|Cancer Cell|2020|683
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
C-Type Lectin DC-SIGN Modulates Toll-like Receptor Signaling via Raf-1 Kinase-Dependent Acetylation of Transcription Factor NF-κB
|Immunity|2007|573
Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-κB activation through Raf-1 and Syk
|Nature Immunology|2009|482
Metabolic pathways in T cell activation and lineage differentiation
|Seminars in Immunology|2016|479